



Orencia

HMSAMCD- Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-237-5512.** If you have questions regarding the prior authorization, please contact CVS Caremark at **1-808-254-4414**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date:** _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Patient's Phone Number: _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Additional Demographic Information:

Patient Weight: _____ *kg*
Patient Height: _____ *ft* _____ *inches*

Indicate where the drug is being dispensed:

- Office Outpatient Hospital Ambulatory Surgical Inpatient Hospital
- Off Campus Outpatient Hospital Urgent Care Emergency Room Birthing Center
- Military Facility Skilled Nursing Facility Nursing Facility Hospice
- Inpatient Psychiatric Psychiatric Residential Treatment End Stage Renal Facility
- Psychiatric Facility Pharmacy Other

Indicate where the drug is being administered:

- Ambulatory surgical Home Inpatient Hospital
- Office Outpatient Hospital Pharmacy

What is the ICD-10 code? _____

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Orencia HMSAMCD – 04/2026.

CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com

Criteria Questions:

1. Will the requested drug be used in combination with any other biologic (e.g., Humira) or targeted synthetic drug (e.g., Olumiant, Otezla, Xeljanz) for the same indication?
- Yes, *Continue to #2*
- No, *Continue to #2*
2. Has the patient ever received (including current utilizers) a biologic (e.g., Humira) or targeted synthetic drug (e.g., Olumiant, Xeljanz) associated with an increased risk of tuberculosis?
- Yes, *Continue to #9*
- No, *Continue to #3*
3. Has the patient had a tuberculosis (TB) test (e.g., tuberculosis skin test [TST], interferon-release assay [IGRA]) within 12 months of initiating therapy?
- Yes, *Continue to #4*
- No, *Continue to #4*
4. What were the results of the tuberculosis (TB) test?
- Positive for TB, *Continue to #5*
- Negative for TB, *Continue to #9*
- Unknown, *Continue to #9*
5. Which of the following applies to the patient?
- Patient has latent TB and treatment for latent TB has been initiated, *Continue to #9*
- Patient has latent TB and treatment for latent TB has been completed, *Continue to #9*
- Patient has latent TB and treatment for latent TB has not been initiated, *Continue to #9*
- Patient has active TB, *Continue to #9*

Indication

9. What is the diagnosis?
- Rheumatoid arthritis, *Continue to #100*
- Polyarticular juvenile idiopathic arthritis (pJIA), *Continue to #200*
- Oligoarticular juvenile idiopathic arthritis, *Continue to #200*
- Psoriatic arthritis, *Continue to #300*
- Chronic graft versus host disease, *Continue to #400*
- Immune checkpoint inhibitor-related toxicity, *Continue to #500*
- Prophylaxis of acute graft versus host disease, *Continue to #600*
- Systemic juvenile idiopathic arthritis (sJIA), *Continue to Criteria Exception Policy*
- Other, *No Further Questions*

Rheumatoid Arthritis

100. Has the patient been diagnosed with moderately to severely active rheumatoid arthritis (RA)?

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Orenca HMSAMCD – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

Yes, *Continue to #101*

No, *Continue to #101*

101. Is the patient an adult?

Yes, *Continue to #102*

No, *Continue to #102*

102. Is the requested drug being prescribed by or in consultation with a rheumatologist?

Yes, *Continue to #103*

No, *Continue to #103*

Continuation of Therapy

103. Is this request for continuation of therapy with the requested drug?

Yes, *Continue to #104*

No, *Continue to #107*

104. Is the patient currently receiving the requested drug through samples or a manufacturer's patient assistance program?

Yes, *Continue to #107*

No, *Continue to #105*

Unknown, *Continue to #107*

105. Has the patient achieved or maintained a positive clinical response since starting treatment with the requested drug?

Yes, *Continue to #106*

No, *Continue to #106*

106. Has the patient experienced substantial disease activity improvement (e.g., at least 20% from baseline) in tender joint count, swollen joint count, pain, or disability?

Yes, *No Further Questions*

No, *No Further Questions*

Initial Therapy

Prior treatment with another biologic or targeted synthetic drug

107. Has the patient received or is currently receiving a biologic or targeted synthetic drug (e.g., Rinvoq, Xeljanz) within the past 120 days indicated for moderately to severely active rheumatoid arthritis (excluding receiving the drug via samples or a manufacturer's patient assistance program)?

Yes, *No Further Questions*

No, *Continue to #108*

Requirements regarding prior therapy

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Orenicia HMSAMCD – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

108. Does the patient meet either of the following: a) the patient was tested for the rheumatoid factor (RF) biomarker and the RF biomarker test was positive, or b) the patient was tested for the anti-cyclic citrullinated peptide (anti-CCP) biomarker and the anti-CCP biomarker test was positive?

Yes, *Continue to #110*

No, *Continue to #109*

109. Has the patient been tested for all of the following biomarkers: a) rheumatoid factor (RF), b) anti-cyclic citrullinated peptide (anti-CCP), and c) C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR)?

Yes, *Continue to #110*

No, *Continue to #110*

110. Has the patient failed to achieve a low disease activity after a 3-month trial of methotrexate (MTX) monotherapy at a maximum titrated dose of at least 15 mg per week?

Yes, *Continue to #111*

No, *Continue to #117*

111. Has the patient had an inadequate response to methotrexate in combination with at least one other conventional synthetic drug (i.e., hydroxychloroquine and/or sulfasalazine) after a 30-month trial at a maximum tolerated dose(s)?

Yes, *No Further Questions*

No, *Continue to #112*

112. Has the patient experienced an intolerable adverse event to hydroxychloroquine or sulfasalazine?

Yes, *No Further Questions*

No, *Continue to #113*

113. Does the patient have a contraindication to sulfasalazine (e.g., porphyria, intestinal or urinary obstruction)?

Yes, *Continue to #114*

No, *Continue to #116*

114. Does the patient have a contraindication to hydroxychloroquine?

Yes, *Continue to #115*

No, *Continue to #116*

115. Please indicate the contraindication to hydroxychloroquine

Clinical diagnosis of alcohol use disorder, alcoholic liver disease, or other chronic liver disease, *No Further Questions*

Drug interaction, *No Further Questions*

Risk of treatment-related toxicity, *No Further Questions*

Pregnancy or currently planning pregnancy, *No Further Questions*

Breastfeeding, *No Further Questions*

Significant comorbidity prohibits use of systemic agents (e.g., liver or kidney disease, blood dyscrasias, uncontrolled hypertension), *No Further Questions*

Hypersensitivity, *No Further Questions*

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Orenca HMSAMCD – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

History of intolerance or adverse event, *No Further Questions*

116. Does the patient have moderate to high disease activity?

Yes, *No Further Questions*

No, *No Further Questions*

117. Was the patient unable to tolerate a 3-month trial of methotrexate monotherapy at a maximum titrated dose of at least 15 mg per week?

Yes, *Continue to #118*

No, *Continue to #125*

118. Has the patient had an inadequate response to methotrexate in combination with at least one other conventional synthetic drug (i.e., hydroxychloroquine and/or sulfasalazine) after a 3-month trial at a maximum tolerated dose(s)?

Yes, *No Further Questions*

No, *Continue to #119*

119. Has the patient stopped taking methotrexate and has had an inadequate response to another conventional synthetic drug (i.e., leflunomide, hydroxychloroquine, and/or sulfasalazine) alone or in combination after a 3-month trial at a maximum tolerated dose(s)?

Yes, *No Further Questions*

No, *Continue to #120*

120. Has the patient experienced an intolerable adverse event to leflunomide, hydroxychloroquine, or sulfasalazine?

Yes, *No Further Questions*

No, *Continue to #121*

121. Does the patient have a contraindication to sulfasalazine (e.g., porphyria, intestinal or urinary obstruction)?

Yes, *Continue to #122*

No, *Continue to #124*

122. Does the patient have a contraindication to leflunomide and hydroxychloroquine?

Yes, *Continue to #123*

No, *Continue to #124*

123. Please indicate the contraindication to leflunomide and methotrexate

Clinical diagnosis of alcohol use disorder, alcoholic liver disease or other chronic liver disease, *No Further Questions*

Drug interaction, *No Further Questions*

Risk of treatment-related toxicity, *No Further Questions*

Pregnancy or currently planning pregnancy, *No Further Questions*

Breastfeeding, *No Further Questions*

Significant comorbidity prohibits use of systemic agents (e.g., liver or kidney disease, blood dyscrasias, uncontrolled hypertension), *No Further Questions*

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Oencia HMSAMCD – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

- Hypersensitivity, *No Further Questions*
- History of intolerance or adverse event, *No Further Questions*
- Other, *No Further Questions*

124. Does the patient have moderate to high disease activity?

- Yes, *No Further Questions*
- No, *No Further Questions*

125. Has the patient experienced an intolerable adverse event to methotrexate and has discontinued methotrexate?

- Yes, *Continue to #128*
- No, *Continue to #126*

126. Does the patient have a contraindication to methotrexate?

- Yes, *Continue to #127*
- No, *Continue to #127*

127. Please indicate the contraindication to methotrexate

- Clinical diagnosis of alcohol use disorder, alcoholic liver disease or other chronic liver disease, *Continue to #128*
- Drug interaction, *Continue to #128*
- Risk of treatment-related toxicity, *Continue to #128*
- Pregnancy or currently planning pregnancy, *Continue to #128*
- Breastfeeding, *Continue to #128*
- Significant comorbidity prohibits use of systemic agents (e.g., liver or kidney disease, blood dyscrasias, uncontrolled hypertension), *Continue to #128*
- Hypersensitivity, *Continue to #128*
- History of intolerance or adverse event, *Continue to #128*
- Other, *Continue to #128*

128. Has the patient had an inadequate response to another conventional synthetic drug (i.e., leflunomide, hydroxychloroquine, and/or sulfasalazine) alone or in combination after a 3-month trial at a maximum tolerated dose(s)?

- Yes, *No Further Questions*
- No, *Continue to #129*

129. Has the patient experienced an intolerable adverse event to leflunomide, hydroxychloroquine, or sulfasalazine?

- Yes, *No Further Questions*
- No, *Continue to #130*

130. Does the patient have a contraindication to sulfasalazine (e.g., porphyria, intestinal or urinary obstruction)?

- Yes, *Continue to #131*
- No, *Continue to #133*

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Orenca HMSAMCD – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

131. Does the patient have a contraindication to leflunomide and hydroxychloroquine?

Yes, *Continue to #132*

No, *Continue to #133*

132. Please indicate the contraindication to leflunomide and methotrexate

Clinical diagnosis of alcohol use disorder, alcoholic liver disease or other chronic liver disease, *No Further Questions*

Drug interaction, *No Further Questions*

Risk of treatment-related toxicity, *No Further Questions*

Pregnancy or currently planning pregnancy, *No Further Questions*

Breastfeeding, *No Further Questions*

Significant comorbidity prohibits use of systemic agents (e.g., liver or kidney disease, blood dyscrasias, uncontrolled hypertension), *No Further Questions*

Hypersensitivity, *No Further Questions*

History of intolerance or adverse event, *No Further Questions*

Other, *No Further Questions*

133. Does the patient have moderate to high disease activity?

Yes, *No Further Questions*

No, *No Further Questions*

Articular Juvenile Idiopathic Arthritis

200. Has the patient been diagnosed with moderately to severely active articular juvenile idiopathic arthritis?

Yes, *Continue to #201*

No, *Continue to #201*

201. Is the patient 2 years of age or older?

Yes, *Continue to #202*

No, *Continue to #202*

202. Is the requested drug being prescribed by or in consultation with a rheumatologist?

Yes, *Continue to #203*

No, *Continue to #203*

203. Is this request for continuation of therapy with the requested drug?

Yes, *Continue to #204*

No, *Continue to #207*

Continuation of Therapy

204. Is the patient currently receiving the requested drug through samples or a manufacturer's patient assistance program?

Yes, *Continue to #207*

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Oencia HMSAMCD – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

- No, *Continue to #205*
 Unknown, *Continue to #207*

205. Has the patient achieved or maintained positive clinical response to treatment as evidenced by low disease activity or improvement in signs and symptoms of the condition since starting treatment with the requested drug?

- Yes, *Continue to #206*
 No, *Continue to #206*

206. Which of the following has the patient experienced an improvement in from baseline?

- Number of joints with active arthritis (e.g., swelling, pain, limitation of motion), *No Further Questions*
 Number of joints with limitation of movement, *No Further Questions*
 Functional ability, *No Further Questions*
 None of the above, *No Further Questions*

Initial Therapy

Prior treatment with another biologic or targeted synthetic drug

207. Has the patient ever received or is currently receiving a biologic (e.g., Humira) or targeted synthetic drug (e.g., Xeljanz) that is indicated for moderately to severely active articular juvenile idiopathic arthritis (excluding receiving the drug via samples or a manufacturer's patient assistance program)?

- Yes, *No Further Questions*
 No, *Continue to #208*

New starts

208. Has the patient had an inadequate response to methotrexate or another conventional synthetic drug (e.g., leflunomide, sulfasalazine, hydroxychloroquine) administered at an adequate dose and duration?

- Yes, *No Further Questions*
 No, *Continue to #209*

209. Has the patient had an inadequate response to a trial of scheduled non-steroidal anti-inflammatory drugs (NSAIDs) and/or intra-articular glucocorticoids (e.g., triamcinolone hexacetonide)?

- Yes, *Continue to #210*
 No, *Continue to #211*

210. Does the patient have one of the following risk factors for poor outcome: a) involvement of ankle, wrist, hip, sacroiliac joint, and/or temporomandibular joint (TMJ), b) presence of erosive disease or enthesitis, c) delay in diagnosis, d) elevated levels of inflammation markers, or e) symmetric disease?

- Yes, *No Further Questions*
 No, *Continue to #211*

211. Does the patient have any of the following risk factors for disease severity and potentially a more refractory disease course: a) positive rheumatoid factor, b) positive anti-cyclic citrullinated peptide antibodies, or c) pre-existing joint damage?

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Orenca HMSAMCD – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

- Yes, *Continue to #212*
- No, *Continue to #212*

212. Does the patient meet any of the following: a) high-risk joints are involved (e.g., cervical spine, wrist, or hip), b) high disease activity, or c) high risk for disabling joint disease?

- Yes, *No Further Questions*
- No, *No Further Questions*

Psoriatic Arthritis

300. Is the patient 2 years of age or older?

- Yes, *Continue to #301*
- No, *Continue to #301*

301. Is the requested drug being prescribed by or in consultation with a rheumatologist or dermatologist?

- Yes, *Continue to #302*
- No, *Continue to #302*

Continuation of Therapy

302. Is this request for continuation of therapy with the requested drug?

- Yes, *Continue to #303*
- No, *Continue to #306*

303. Is the patient currently receiving the requested drug through samples or a manufacturer's patient assistance program?

- Yes, *Continue to #306*
- No, *Continue to #304*
- Unknown, *Continue to #306*

304. Has the patient achieved or maintained a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition since starting treatment with the requested drug?

- Yes, *Continue to #305*
- No, *Continue to #305*

305. Which of the following has the patient experienced an improvement in from baseline?

- Number of swollen joints, *No Further Questions*
- Number of tender joints, *No Further Questions*
- Dactylitis, *No Further Questions*
- Enthesitis, *No Further Questions*
- Skin and/or nail involvement, *No Further Questions*
- Functional status, *No Further Questions*
- C-reactive protein (CRP), *No Further Questions*

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Orenca HMSAMCD – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

None of the above, *No Further Questions*

Initial Therapy

306. Has the patient been diagnosed with active psoriatic arthritis (PsA)?

Yes, *Continue to #307*

No, *Continue to #307*

Prior treatment with another biologic or targeted synthetic drug

307. Has the patient ever received (including current utilizers) a biologic (e.g., Humira) or targeted synthetic drug (e.g., Rinvoq, Otezla) that is indicated for active psoriatic arthritis (excluding receiving the drug via samples or a manufacturer's patient assistance program)?

Yes, *No Further Questions*

No, *Continue to #308*

New starts

308. What is the patient's disease severity?

Mild to moderate, *Continue to #309*

Severe, *No Further Questions*

309. Does the patient have enthesitis?

Yes, *No Further Questions*

No, *Continue to #310*

310. Has the patient had an inadequate response to methotrexate, leflunomide, or another conventional synthetic drug (e.g., sulfasalazine) administered at an adequate dose and duration?

Yes, *No Further Questions*

No, *Continue to #311*

311. Has the patient had an intolerance to methotrexate, leflunomide, or another conventional synthetic drug (e.g., sulfasalazine)?

Yes, *No Further Questions*

No, *Continue to #312*

312. Does the patient have a contraindication to methotrexate or leflunomide?

Yes, *Continue to #313*

No, *Continue to #314*

313. Please indicate the contraindication

Clinical diagnosis of alcohol use disorder, alcoholic liver disease or other chronic liver disease, *No Further Questions*

Drug interaction, *No Further Questions*

Risk of treatment-related toxicity, *No Further Questions*

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Orenica HMSAMCD – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

- Pregnancy or currently planning pregnancy, *No Further Questions*
- Breastfeeding, *No Further Questions*
- Significant comorbidity prohibits use of systemic agents (e.g., liver or kidney disease, blood dyscrasias, uncontrolled hypertension), *No Further Questions*
- Hypersensitivity, *No Further Questions*
- History of intolerance or adverse event, *No Further Questions*
- Other, *No Further Questions*

314. Does the patient have a contraindication to another conventional synthetic drug (e.g., sulfasalazine)?

- Yes, *No Further Questions*
- No, *No Further Questions*

Chronic Graft Versus Host Disease

400. Is the requested drug being prescribed by or in consultation with an oncologist or hematologist?

- Yes, *Continue to #401*
- No, *Continue to #401*

Continuation of Therapy

401. Is this request for continuation of therapy with the requested drug?

- Yes, *Continue to #402*
- No, *Continue to #404*

402. Is the patient currently receiving the requested drug through samples or a manufacturer's patient assistance program?

- Yes, *Continue to #404*
- No, *Continue to #403*
- Unknown, *Continue to #404*

403. Has the patient achieved or maintained a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition since starting treatment with the requested drug?

- Yes, *No Further Questions*
- No, *No Further Questions*

Initial Therapy

404. Has the patient experienced an inadequate response to systemic corticosteroids?

- Yes, *No Further Questions*
- No, *Continue to #405*

405. Does the patient have an intolerance or contraindication to corticosteroids?

- Yes, *No Further Questions*
- No, *No Further Questions*

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Orencia HMSAMCD – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

Immune checkpoint inhibitor-related toxicity

500. Is the requested drug being prescribed by or in consultation with an oncologist or hematologist?

Yes, *Continue to #501*

No, *Continue to #501*

501. Does the patient have myocarditis?

Yes, *Continue to #502*

No, *Continue to #502*

502. Has the patient experienced an inadequate response to systemic corticosteroids?

Yes, *No Further Questions*

No, *Continue to #503*

503. Does the patient have an intolerance or contraindication to corticosteroids?

Yes, *No Further Questions*

No, *Continue to #504*

504. Does the patient have concomitant myositis and the requested drug will be used in combination with ruxolitinib?

Yes, *No Further Questions*

No, *No Further Questions*

Prophylaxis of acute graft versus host disease

600. Is the patient 2 years of age or older?

Yes, *Continue to #601*

No, *Continue to #601*

601. Is the requested drug being prescribed by or in consultation with an oncologist or hematologist?

Yes, *Continue to #602*

No, *Continue to #602*

602. Is the patient undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor?

Yes, *Continue to #603*

No, *Continue to #603*

603. Will the requested medication be used in combination with a calcineurin inhibitor (e.g., cyclosporine, tacrolimus) and methotrexate?

Yes, *No Further Questions*

No, *No Further Questions*

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Orenca HMSAMCD – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X _____

Prescriber or Authorized Signature

Date (mm/dd/yy)

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Orenca HMSAMCD – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**